Prescriber's Corner

Omacetaxine Mepesuccinate: A New Treatment Option for Patients With Chronic Myelogenous Leukemia

Sandra E. Kurtin, RN, MS, AOCN®, ANP-C, and Lisa Matta, RN, MSN

From University of Arizona Cancer Center, Tucson, Arizona

Ms. Kurtin has acted as a consultant for Teva; Ms. Matta has acted as an advisor for Teva.

Correspondence to: Sandra E. Kurtin, RN, MS, AOCN®, ANP-C, University of Arizona Cancer Center, 6950 North Chaparral Place, Tucson, AZ 85718. E-mail: skurtin@umcaz.edu


From University of Arizona Cancer Center, Tucson, Arizona | DOI: 10.6004/jadpro.2013.4.4.6 | © 2013 Harborside Press®


  

ABSTRACT

Recently, the FDA approved omacetaxine mepesuccinate (Synribo) for use in adult patients with chronic- or accelerated-phase chronic myelogenous leukemia with resistance and/or intolerance to two or more tyrosine kinase inhibitors. Learn about the mechanism of action, key trials, management strategies, and response evaluation for patients receiving omacetaxine.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here